Ixazomib, daratumumab and low-dose dexamethasone in intermediate-fit patients with newly diagnosed multiple myeloma: an open-label phase 2 trialResearch in context

Summary: Background: The outcome of non-transplant eligible newly diagnosed multiple myeloma (NDMM) patients is heterogeneous, partly depending on frailty level. The aim of this study was to prospectively investigate the efficacy and safety of Ixazomib-Daratumumab-low-dose dexamethasone (Ixa-Dara-d...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. van Kampen, Rineke B.L. Leys, Noortje Thielen, Matthijs Westerman, Ka-Lung Wu, Inge Ludwig, Djamila E. Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Gert-Jan Timmers, Fransien de Boer, Lidwine W. Tick, Annelies Verbrugge, Danny Buitenhuis, Sonia M. Cunha, Ellen van der Spek, Esther G.M. de Waal, Maaike Sohne, Pieter Sonneveld, Inger S. Nijhof, Saskia K. Klein, Niels W.C.J. van de Donk, Mark-David Levin, Paula F. Ypma, Sonja Zweegman
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-09-01
Serija:	EClinicalMedicine
Teme:	Multiple myeloma Elderly Daratumumab Ixazomib Intermediate-fit IMWG frailty index
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589537023003449
Oznake:	Označite Brez oznak, prvi označite!